Holen Sie sich die Stockscreener-App
6.26
4.13%
-0.27
Schlusskurs vom Vortag:
$6.53
Offen:
$6.57
24-Stunden-Volumen:
14,050
Relative Volume:
0.21
Marktkapitalisierung:
$107.54M
Einnahmen:
$37.16M
Nettoeinkommen (Verlust:
$-17.83M
KGV:
-6.0542
EPS:
-1.034
Netto-Cashflow:
$-14.22M
1W Leistung:
+2.04%
1M Leistung:
+8.87%
6M Leistung:
-21.21%
1J Leistung:
-28.25%
1-Tages-Spanne:
$6.26
$6.57
1-Wochen-Bereich:
$5.90
$6.79
52-Wochen-Spanne:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.26 | 107.54M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals holds the spotlight after recent market context - ad-hoc-news.de
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
VRCAVerrica Pharmaceuticals Inc Latest SEC Filings - Finviz
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell 3000E Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Price to book forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0 - TradingView
Price to sales forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Price to earnings ratio of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA) - TradingView
VRCA Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0) - TradingView
1NE0 Forecast — Price Target — Prediction for 2027 - TradingView
A41A98 Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion - MyChesCo
Verrica Pharmaceuticals Inc (VRCA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
H.C. Wainwright reiterates Verrica stock rating on trial progress - Investing.com UK
Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts - The Dermatology Digest
H.C. Wainwright reiterates Verrica stock rating on trial progress By Investing.com - Investing.com Australia
Verrica Pharmaceuticals (VRCA) Advances 3.19% as Stock Approaches Resistance at $6.11Dynamic Hedging - dars.gov.et
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica doses first U.S. patient in common warts trial By Investing.com - Investing.com South Africa
Verrica doses first U.S. patient in common warts trial - Investing.com
Verrica starts Phase 3 common-warts trial with first U.S. patient - Stock Titan
Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
Verrica Pharmaceuticals (VRCA) Holds Steady Near $6.0, Eyeing Resistance at $6.3Put Dominated - newsline.com
Verrica Pharmaceuticals Stockoperations and strategy in focus after YCANTH launch - Ad-hoc-news.de
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV - TipRanks
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
Verrica (VRCA) director Diem Nguyen awarded 16,000 stock options at $6.04 - Stock Titan
Verrica (VRCA) CMO receives 233,840 performance-vested stock options - Stock Titan
Verrica (VRCA) COO receives 171,340 stock options with price hurdles - Stock Titan
Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles - Stock Titan
Director Gavin Corcoran receives 16,000 Verrica (VRCA) stock options at $6.04 - Stock Titan
Verrica Pharmaceuticals (NASDAQ: VRCA) shareholders approve new equity plan and re-elect directors - Stock Titan
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):